Epibatidine: Pharmacological properties of a novel nicotinic acetylcholine receptor agonist and analgesic agent

CNS Drug Reviews

Volumn 2, Issue 1, 1996, Pages 21-39

  Sullivan, James P ^a   Bannon, Anthony W ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

analgesia; epibatidine; ion channels; nicotinic receptor

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; ALPHA BUNGAROTOXIN; ANALGESIC AGENT; ATROPINE; CHLORISONDAMINE; CYTISINE; DIHYDRO BETA ERYTHROIDINE; EPIBATIDINE; HEXAMETHONIUM; ION CHANNEL; MECAMYLAMINE; NALOXONE; NEUROTOXIN; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; PEMPIDINE; RADIOLIGAND; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; S 1663; SCOPOLAMINE; UNCLASSIFIED DRUG; YOHIMBINE;

ANALGESIA; CARDIOVASCULAR SYSTEM; COGNITION; DRUG TARGETING; HUMAN; LIGAND BINDING; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RECEPTOR AFFINITY; REVIEW;

EID: 0029921513     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1996.tb00288.x     Document Type: Review

References (68)

1. Alkondon M, Albuquerque EX. Enantiomers of epibatidine as potent nicotinic agonists at two identified subtypes of nicotinic acetylcholine receptors (nAChRs) in rat hippocampal neurons. Soc Neurosci 1994;20:467.8.
2. 3H]ABT-418: A novel cholinergic channel ligand. J Pharmacol Exp Ther, 1995;273:1434-1441.
3. Arneric SP, Sullivan JP, Briggs CA, et al. (S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl)Isoxazole (ABT-418): A novel cholinergic ligand with cognition enhancing and anxiolytic activity. I. In vitro activity. J Pharmacol Exp Ther 1994;270:310-317.
4. Arneric SP, Sullivan JP, Williams M. Neuronal nicotinic acetylcholine receptors: Novel targets for CNS therapeutics. In Bloom F E and Kupfer D J eds. Psychopharmacology: Fourth Generation of Progress, Vol. 5. New York: Raven, 1995;94-110.
5. Arneric SP, Williams M. Nicotinic agonists in Alzheimer's disease: Does the molecular diversity of nicotine receptors offer the opportunity for developing CNS-selective cholinergic channel activators? In Racagni G, Brunello N, Langer S Z eds. Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction., Vol. 7. Basel: Karger, 1994;58-70.
6. Badio B, Daly JW. Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 1994;45:563-569.
7. Badio B, Garraffo HM, Spande TF, Daly JW, Epibatidine: Discovery and definition as a potent analgesic and nicotinic agonist. Med Chem Res 1994;4:440-448.
8. Bannon AW, Gunther KL, Decker MW. Is epibatidine really analgesic? Dissociation of the locomotor activity, temperature, and analgesic effects of (±)-epibatidine. Pharmacol Biochem Behav 1995;51:693-698.
9. Bannon AW, Gunther KL, Decker MW, Arneric SP. The influence of Bay K 8644 treatment on (±)-epibatidine-induced analgesia. Brain Res 1995;678:244-250.
10. Beani L, Bianchi C, Ferraro L, et al. Effect of nicotine on the release of acetylcholine and amino acids in the brain. Prog Brain Res 1989;79:149-155.
11. Benowitz NL. Nicotine and coronary heart disease. Trends Cardiovasc Med 1992;1:315-321.
12. Bonhaus DW, Bley KR, Broka CA, et al. Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine. J Pharmacol Exp Ther 1995;272:1199-1203.
13. Boulton BA, Thinschmidt JS, Quintana R, Meyer EM, Papke RL. The pharmacology of epibatidine and ABT-418 on putative subtypes of rat neuronal nicotinic receptors. Mol Pharmacol 1996, in press.
14. Briggs CA, McKenna DG, Piattoni-Kaplan M. Human a7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology, 1996; in press.
15. Brioni JD, Arneric SP. Nicotinic receptor agonists facilitate retention of avoidance training: Participation of dopaminergic mechanisms. Behav Neural Biol 1993;59:57-62.
16. Brioni JD, O'Neill A, Kim KJB, Buckley MJ, Decker MW, Arneric SP. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418. J Pharmacol Exp Ther 1994;271:353-361.
17. Brioni JK, O'Neill AB, Kim DJB, Decker MW. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 1993;238:1-8.
18. Broka CA. Synthetic approaches to epibatidine. Med Chem Res 1994;4:449-460.
19. 125I]-L-bungarotoxin. J Neurosci 1985;5:1307-1315.
20. Corey EJ, Loh TP, Achutha Rao S, Daley DC, Sarshar S. Stereocontrolled total synthesis of (+) and (-)-epibatidine. J Org Chem 1993;58:5600-5604.
21. Damaj MI, Creasy KR, Grove AD, Rosecrans JA, Martin BR. Pharmacological effects of epibatidine optical enantiomers. Brain Res 1994;664:34-40.
22. Damaj MI, Creasy KR, Rosecrans J, Martin BR. Pharmacological effects of epibatidine, a potent nicotinic agonist. In Clarke P B S, Quik M, Thurau K, Adlkofer F eds. International Symposium on Nicotine: The Effects of Nicotine on Biological Systems II., Montreal: Birkhauser Verlag, 1994 P33.
23. Damaj MI, Tucker SM, Aceto MD, Martin BR. Analgesic activity of epibatidine and its enantiomers in a chemical model of pain in mice. Med Chem Res 1994;4:483-492.
24. Damaj MI, Welch SP, Martin BR. Involvement of calcium and L-type channels in nicotine-induced antinociception. J Pharmacol Exp Ther 1993;266:1330-1338.
25. Decker MW, Brioni JD, Sullivan JP et al. (S)-3-Methyl-5-(1-Methyl-2-Pyrrolidinyl)Isoxazole(ABT-418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther 1994;270:319-328.
26. Decker MW, Majchrzak MJ, Anderson DJ. Effects of nicotine on spatial memory deficits in rats with medial septal lesions. Brain Res 1992;572:281-285.
27. Decker MW, Mc Gaugh JL. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991;7:151-168.
28. Deneris ES, Connolly J, Rogers SW, Duvoisin R. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol Sci 1991;12:34-40.
29. Elogoyhen AB, Johnson D, Boulter J, Vetter D, Heineman SF. Alpha-9: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell 1994;79:705-715.
30. Fischer M, Huangfu D, T.Y.S, Guynet PG. Epibatidine, an alkaloid from the poison frog Epipedobates tricolor, is a powerful ganglionic depolarizing agent. J Pharmacol Exp Ther 1994;270:702-708.
31. Flores CM, Rogers SW, Pabreza LA, Wolfe B, Kellar KJ. A subtype of nicotinic cholinergic receptor is composed of α4 and β2 subunits and is upregulated by chronic nicotine treatment. Mol Pharmacol 1992;41:31-37.
32. Gerzanich V, Anand R, Lindstrom J. Homomers of α8 and α7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties. Mol Pharmacol 1994;45:212-220.
33. Gerzanich V, Peng X, Wells G, et al. Comparative pharmacology of epibatidine, a potent selective agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol 1995;48:776-782.
34. Glennon RA, Herndon JL, Dukat M. Epibatidine-aided studies towards definition of a nicotine receptor pharmacophore. Med Chem Res 1994;4:461-473.
35. Gopalakrishnan M, Buisson B, Touma E, et al. Pharmacological characterization of the human a7 neuronal nicotinic acetylcholine receptor subtype stably expressed in a mammalian cell line. Eur J Pharmacol 1995;290:237-246.
36. 3H]dopamine release from synaptosomes prepared from mouse striatum. J Neurochem 1992;59:848-856.
37. 3H]Epibatidine binding to nicotinic cholinergic receptors in brain. Med Chem Res 1994;4:538-546.
38. Li T, Qian C, Eckman J, Huang DF, Shen TY. The analgesic effect of epibatidine and isomers. Bioorg Med Chem Lett 1993;3:2759-2764.
39. Linville DG, Williams S, Raszkiewicz JR, Arneric SP. Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow. J Pharmacol Exp Ther 1993;267:440-448.
40. Lloyd GK, Mc Donald IA, Vernier JM, et al. Subtype selective cholinergic channel agonists as potential antiparkinson agents. In: The Cholinergic Synapse: Structure, Function and Regulation, 1994; S45.
41. Luetje CW, Harvey SC, Maddox F. Mapping determinants of competitive antagonist sensitivity on neuronal nicotinic receptor subunits. In Clarke PBS, Quik M, Thorseau K, Alkondon F eds. International Symposium on Nicotine: The Effects of Nicotine on Biological Systems II. Basel: Birkhausar Verlag, 1994:13.
42. Luetje CW, Patrick J. Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci 1991;11:837-845.
43. Lukas RJ. Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal cell line. J Pharmacol Exp Ther 1993;265:294-302.
44. Macallan DR, Lunt GG, Wonnacott S, Swanson KL, Rapoport H, Albuquerque EX. Methyllycaconitine and (+)-anatoxin-A differentiate between nicotinic receptors in vertebrate and invertebrate nervous systems. FEBS Lett 1988;226:357-363.
45. Marks MJ, Garnham DA, Grady SR, Collins AC. Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synaptosomes. J Pharmacol Exp Ther 1993;264:542-552.
46. Marks MJ, Stitzel A, Romm E, Wehner JM, Collins AC. Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine, and α-bungarotoxin. Mol Pharmacol 1986;30:427-436.
47. Martin WR. Pharmacology of opioid receptors. Pharmacol Rev 1983;35:283-323.
48. 3H]epibatidine Med Chem Res 1994;4:528-537.
49. Meyer EM, de Fiebre CM, Hunter BE, Simpkins CE, Frauworth N, de Fiebre NEC. Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev Res 1994;31: 127-134.
50. 3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 1991;41:9-12.
51. Papke RL, deFiebre CM, Moulton BA, Thinschmidt JS, Quintana JS, Meyer EM. Activation and inhibition of neuronal nAChRs by potential therapeutic agents. Soc Neurosci 1995:21.
52. Qian C, Chen S, Libertine-Garahan L, Wypij DM. Effects of epibatidine on body weight in mice. Med Chem Res 1994;4:493-501.
53. Qian C, Li T, Shen TY, Libertine-Garahan L, Eckman J, Biftu T, Ip S. Epibatidine is a nicotinic analgesic. Eur J Pharmacol 1993;250:R13-R14.
54. Rupniak NMJ, Patel S, Marwood R, et al. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. Br J Pharmacol 1994;113:1487-1493.
55. Sahley TL, Bernston GG. Antinociceptive effects of central and systemic administration of nicotine in the rat. Psychopharmacology 1979;65:279-283.
56. Sargent PB. The diversity of neuronal nicotinic acetylcholine receptors. Ann Rev Neurosci 1993;16:403-443.
57. Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Partick JW. Molecular cloning, functional properties and distribution of rat brain a7; a nicotinic cation channel highly permeable to calcium. J Neurosci 1993;13:596-604.
58. Senokuchi K, Nakai H, Kawamura M, et al. Synthesis and biological evaluation of (±)-epibatidine and the congeners. Syn Lett 1994;343-344.
59. Spande TF, Garraffo HM, Edwards MW, Yeh HJC, Pannell L, Daly JW. Epibatidine: A novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. J Am Chem Soc 1992;114:3475-3478.
60. Sullivan JP, Briggs CA, Donnelly-Roberts D, et al. (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med Chem Res 1994;4: 502-516.
61. Sullivan JP, Decker MW, Brioni JD, et al. (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J Pharmacol Exp Ther 1994;271:324-331.
62. Sullivan JP, Monteggia LM, Anderson DJ, Giordano TG, Arneric SP, Gopalakrishnan M. Stable expression and pharmacologic properties of the human neuronal nicotinic acetylcholine receptor alpha4beta2 subtype. FASEB J 1995;9:S2262.
63. Whiting P, Schoepfer R, Lindstrom J, Priestly T. Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expressed in mouse fibroblasts. Mol Pharmacol 1992;40:463-472.
64. Wong ET, Holstad SG, Mennerick SJ, Hong SE, Zorumski CF, Isenberg KE. Pharmacological and physiological properties of a putative ganglionic nicotinic receptor, α3β4, expressed in transfected eucaryotic cells. Mol Brain Res 1995;28:101-109.
65. Wonnacott S, Albuquerque EX, Bertrand D. Methyllycaconitine: A new probe that discriminates between nicotinic acetylcholine receptor subclasses. Meth Neurosci 1993;12:263-275.
66. Wonnacott S, Drasdo A, Sanderson E, Rowell P. Presynaptic nicotinic receptors and the modulation of transmission release. In G. B. a. J. Marsh (Eds.), The Biology of Nicotine Dependence. Chichester: Wiley, 1990:87-105.
67. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG. Presynaptic modulation of transmitter release by nicotinic receptors. In Nordberg A., Fuxe K., Holmstedt B., Sundwall A. eds. Progress in Brain Research Amsterdam: Elsevier, 1990;80:157-163.
68. Wonnacott S, Jackman JL, Swanson KL, Rapoport H, Albuquerque EX. Nicotinic pharmacology of anatoxin analogs II. Side chain structure-activity relationships at neuronal nicotinic ligand binding sites. J Pharmacol Exp Ther 1991;259:387-391.